Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa Study to Evaluate the Safety, Tolerability, and Efficacy of EPI-001 in Patients With Androgenetic Alopecia

NCT07618195 is registered in ClinicalTrials.gov with Epibiotech as lead sponsor.

NCT NCT07618195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07618195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa Study to Evaluate the Safety, Tolerability, and Efficacy of EPI-001 in Patients With Androgenetic Alopecia
Lead sponsor
Epibiotech
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 12, 2026
Completion date
June 1, 2029
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

androgenetic alopecia